echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Hualing Pharmaceutical's first in class hypoglycemic drug Dopaglietin (Hua Doning) was approved for listing

    Hualing Pharmaceutical's first in class hypoglycemic drug Dopaglietin (Hua Doning) was approved for listing

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 8, the first in class hypoglycemic drug dorzagliatin developed by Hua Ling Pharmaceutical was officially approved for marketing


     

    Dopaglietin is a world-first glucokinase initiator (GKA) designed to control the progressive degenerative properties


    Doglidine molecular structure

    A phase III clinical study code-named SEED evaluated the efficacy


    The results showed that at week 24, the saccharified hemoglobin (HbA1c) in the treatment group decreased by 1.


    Another key phase III study (DAWN) evaluated the efficacy


    The results showed that at week 24, HbA1c was reduced by 1.


    In August 2020, Hualing Pharmaceutical and Bayer reached a cooperation to be responsible for clinical development, registration, product supply and distribution as the holder of the drug marketing license


    Hua Ling Pharmaceutical will receive an advance payment of RMB300 million, in addition to an additional milestone payment


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.